Magellan Rx Management announces biosimilar program saved US$40 million

Jun 9, 2021

Magellan Rx Management announced that its oncology biosimilar medical benefit drug management solution has saved customers over US$40 million, with greater savings expected as the market shift to biosimilars accelerates.

Print Page Mail Article